Discontinuation of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis and Excellent Disease Control

Siri Lillegraven; Nina Paulshus Sundlisæter; Anna-Birgitte Aga; Joseph Sexton; Daniel H Solomon; Désirée van der Heijde; Espen A Haavardsholm

doi:10.1001/jama.2023.0492

Discontinuation of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis and Excellent Disease Control

JAMA. 2023 Mar 28;329(12):1024-1026. doi: 10.1001/jama.2023.0492.

Authors

Siri Lillegraven¹, Nina Paulshus Sundlisæter¹, Anna-Birgitte Aga¹, Joseph Sexton¹, Daniel H Solomon², Désirée van der Heijde³, Espen A Haavardsholm¹

Affiliations

¹ Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway.
² Division of Rheumatology, Brigham and Women's Hospital, Boston, Massachusetts.
³ Leiden University Medical Centre, Department of Rheumatology, Leiden, the Netherlands.

No abstract available

Plain language summary

This open-label randomized clinical trial assessed the 12-month risk of disease activity flares after discontinuation of conventional synthetic DMARDs (csDMARDs) compared with continuing half-dose csDMARDs in adult Norwegian patients with rheumatoid arthritis and excellent disease control.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antirheumatic Agents* / therapeutic use
Arthritis, Rheumatoid* / drug therapy
Biological Products / therapeutic use
Drug Therapy, Combination
Humans
Methotrexate / therapeutic use
Treatment Outcome
Withholding Treatment*

Substances

Antirheumatic Agents
Biological Products
Methotrexate